Gland Pharma`s Generic Angiotensin II Receives Approval in the U.S.
FDA Confirms Paragraph IV Patent Litigation for Angiotensin II Acetate
The European Medicines Agency’s (EMA) latest human medicines committee (CHMP) decisions have been announced, including recommendations for three medicines and one rejection for a marketing authorisation. The Committee also recommended granting a marketing authorisation for La Jolla’s Giapreza, among other decisions.
La Jolla Pharmaceuticals $LJPC has landed $125 million to back its rollout of Giapreza, a new drug for dangerously low blood pressure that was green-lighted by the FDA late last year.
La Jolla Pharmaceutical Company announced that the U.S. Food and Drug Administration (FDA) have approved GiaprezaTM (angiotensin II) to increase blood pressure in adults with septic or other distributive shock.